Navigation Links
N30 Pharmaceuticals to Present S-Nitrosoglutathione Reductase Inhibitor Preclinical Safety Data at 2011 Society of Toxicology 50th Anniversary Meeting
Date:3/2/2011

BOULDER, Colo., March 2, 2011 /PRNewswire/ -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011. The data describe the preclinical safety evaluation of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR), and the lack of apparent mechanism-based toxicities. GSNOR is a critical enzyme in the endogenous nitric oxide pathway, and its activity is thought to be important in human respiratory, gastrointestinal and cardiovascular disease.  N30 Pharma's first GSNOR inhibitor, N6022, is currently in Phase 1b/2a testing. The poster will be available as a PDF on the N30 Pharma website after its presentation (www.n30pharma.com).

Event:  2011 Annual Meeting of the Society of Toxicology

Session Title and Date:  Pharmaceutical Safety Assessment:  Therapeutic Agents, March 7, 2011, 1 pm EST.

Poster:  Inhibition of the Enzyme S-nitrosoglutathione Reductase  (GSNOR) Does Not Cause Mechanism-Based Toxicity.  

Targeting GSNOR

GSNOR breaks down S-nitrosoglutathione (GSNO), reducing the body's pool of GSNO. In the lung, GSNO likely plays an important role in maintaining normal respiratory function through its influence on bronchial tone and anti-inflammatory effects. Similarly, in the gut, GSNO supports barrier function and maintains the integrity of the gut surface. In asthmatics, GSNOR up-regulation and decreased GSNO levels have been shown to contribute to respiratory disease, and genetic variants of GSNOR have been correlated with disease susceptibility and poor response to therapy. GSNO has also been found to be important in the cardiovascular system as well as the control of breathing.

About inhibitors of GSNOR

N30 Pharma's portfolio of proprietary compounds provides a platform of potent, selective and reversible inhibitors of GSNOR. They increase levels of GSNO, an S-nitrosothiol that plays a central role in health and disease.


'/>"/>
SOURCE N30 Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. Anadys Pharmaceuticals to Present at the Cowen & Company Healthcare Conference
3. Access Pharmaceuticals to Host Update Conference Call for Investors
4. Optimer Pharmaceuticals to Present at March 2011 Investor Conferences
5. Jazz Pharmaceuticals Announces Fourth Quarter and Full Year 2010 Results Conference Call on March 7
6. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
9. Endo Pharmaceuticals Raises 2011 Financial Guidance and Reports Strong Fourth Quarter 2010 Financial Results
10. MAP Pharmaceuticals to Present Data on LEVADEX™ at the 63rd Annual Meeting of the American Academy of Neurology
11. Savient Pharmaceuticals Announces U.S. Launch of KRYSTEXXA™; Reports Fourth Quarter and Year-End 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... SAN DIEGO and PALMA, ... Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical ... announced that the first patient has been enrolled ... of lead candidate, SNF472, for the treatment of ... haemodialysis (HD). Most ESRD patients, in ...
(Date:1/23/2017)... Jan. 23, 2017 Just two weeks remain until legal experts ... gather in Central London to discuss the flow ... in the market, Parallel Trade 2017 . In the ... of attendees which is available to read in the event download ... Some of ...
(Date:1/21/2017)... ResMed (NYSE: RMD ), BMC ( ... Florida ) today announced they have agreed on a global ... be permitted to sell their existing products in exchange for royalty ... to 3B to close the Florida litigation ... of liability or wrongdoing by any party. The ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... Old School Labs™, makers of the wildly ... Physique bodybuilder Breon Ansley to its growing team of brand ambassadors. The Olympia top ... and in less than a year was able to turn professional, participating in the ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... (SNP) has launched online education programs and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources ... benefits of a seafood-rich diet. These resources have been developed for use ...
(Date:1/22/2017)... ... , ... Zifam Pinnacle, an Australian company dedicated to providing a unique range ... at the January ECRM Trade Show in Hilton Head, SC. , Zifam Pinnacle develops ... all of its creations to help create a more traditional and natural approach to ...
(Date:1/21/2017)... California (PRWEB) , ... January 21, 2017 , ... "ProDOF is the perfect set of ... subject to another subject in a scene," said Christina Austin - CEO of Pixel Film ... given scene. Easily create the illusion of a DSLR racking focus from one area ...
(Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
Breaking Medicine News(10 mins):